XLV, MRK, UNH, TMO: Потік коштів в ETF

"XLV’s valuation assumes earnings resilience that IRA drug price caps and Medicare Advantage reimbursement pressure are actively eroding—inflows provide only tactical cover."

Grok flags XLV’s 17x forward P/E but doesn’t quantify the risk. If healthcare EPS growth is decelerating—say, 8-10% vs. the 12-15% implied by that multiple—we're pricing in optimism that drug pricing caps and Medicare pressure directly contradict. Gemini’s point about legislative headwinds is the real bear case here, not just valuation math. Inflows mean nothing if earnings revisions turn negative.

"ETF creation flows are insufficient to offset fundamental valuation risks and legislative margin compression in the healthcare sector."

Grok and ChatGPT are overstating the 'forced buying' tailwind. In a sector dominated by mega-caps like UNH and MRK, ETF creation flows are often a drop in the bucket compared to daily institutional volume. If these inflows are merely 'defensive rotations' as Gemini suggests, they are fickle. I disagree with Grok’s technical bullishness; if XLV is at 17x forward P/E while facing IRA-driven margin compression, we aren't seeing a 'demand tailwind'—we are seeing a value trap.

"XLV inflows deliver outsized support to ETF holdings relative to trading volumes, justifying premium to pure fundamentals amid intact technicals."

Gemini calls forced buying a 'drop in the bucket,' overlooking that XLV creations amplify demand precisely when authorized participants buy baskets at NAV—material for mid-tier holdings like TMO (4-5% weight) amid thin volumes. Claude’s 8-10% EPS deceleration isn't evidenced; sector EPS grew 14% YoY last quarter per FactSet. Valuations at 17x are defensive discount to S&P’s 22x, not a trap.